Thomas Jefferson University

Thomas Leist

TitleProfessor
InstitutionThomas Jefferson University
DepartmentNeurology - Thomas Jefferson University
Address900 Walnut Street
Philadelphia PA 19107
Phone2159556871
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort. Mult Scler. 2024 Dec 17; 13524585241302170. PMID: 39690897.
      Citations:    
    2. Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, di Cantogno EV. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 Aug 03. PMID: 37535336.
      Citations:    
    3. Leist TP, Cole M, Verma S, Keenan A, Le HH. A retrospective claims analysis of fatigue in patients with multiple sclerosis on disease-modifying therapy. Mult Scler Relat Disord. 2023 Jul 24; 78:104917. PMID: 37597349.
      Citations:    
    4. Kalatskaya I, Giovannoni G, Leist T, Cerra J, Boschert U, Rolfe PA. Revealing the immune cell subtype reconstitution profile in patients from the CLARITY study using deconvolution algorithms after cladribine tablets treatment. Sci Rep. 2023 May 18; 13(1):8067. PMID: 37202447.
      Citations:    
    5. Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 Apr 03; 13524585231161494. PMID: 37012898.
      Citations:    
    6. Reder AT, Stuve O, Tankou SK, Leist TP. T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy. Mult Scler. 2022 Nov 28; 13524585221134216. PMID: 36440826.
      Citations:    
    7. Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist TP, Coyle PK, Dangond F, Alexandri N, Galazka A. Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5?years: a plain language summary. Neurodegener Dis Manag. 2022 12; 12(6):303-310. PMID: 36017797.
      Citations:    
    8. Bijoux Leist J, Leist TP. Multiple sclerosis: relationship between locus of control and quality of life in persons with low versus high disability. Health Psychol Behav Med. 2022; 10(1):316-334. PMID: 35309243.
      Citations:    
    9. Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson LA, Leist TP. Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary. Neurodegener Dis Manag. 2022 Feb 01; 12(1):1-7. PMID: 35019731.
      Citations:    
    10. Giovannoni G, Coyle PK, Vermersch P, Walker B, Aldridge J, Nolting A, Galazka A, Lemieux C, Leist TP. Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets. Front Immunol. 2021; 12:763433. PMID: 35003076.
      Citations:    
    11. Weinstock-Guttman B, Bermel R, Cutter G, Freedman MS, Leist TP, Ma X, Kile D, Musch B, Reder AT, Wolinsky JS. Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Mult Scler. 2021 Aug 12; 13524585211035740. PMID: 34382875.
      Citations:    
    12. Shahrampour S, Heholt J, Wang A, Vedaei F, Mohamed FB, Alizadeh M, Wang Z, Zabrecky G, Wintering N, Bazzan AJ, Leist TP, Monti DA, Newberg AB. N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis. Heliyon. 2021 Jul; 7(7):e07615. PMID: 34377857.
      Citations:    
    13. Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson LA, Leist TP. Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. Mult Scler J Exp Transl Clin. 2021 Jul-Sep; 7(3):20552173211024298. PMID: 34345436.
      Citations:    
    14. De Stefano N, Sormani MP, Giovannoni G, Rammohan K, Leist T, Coyle PK, Dangond F, Keller B, Alexandri N, Galazka A. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies. Mult Scler. 2021 May 10; 13524585211010294. PMID: 33969750.
      Citations:    
    15. Freedman MS, Coyle PK, Comi G, L Scarberry S, Damian D, Hyvert Y, Dangond F, Galazka A, Jack D, Lebson LA, Leist TP. Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Mult Scler J Exp Transl Clin. 2021 Jan-Mar; 7(1):2055217321990852. PMID: 33717501.
      Citations:    
    16. Péloquin S, Schmierer K, Leist TP, Oh J, Murray S, Lazure P. Challenges in multiple sclerosis care: Results from an international mixed-methods study. Mult Scler Relat Disord. 2021 May; 50:102854. PMID: 33690086.
      Citations:    
    17. Berger JR, Leist TP, Greenberg BM, Rammohan K. Physician Compensation in the United States - Through the Lens of the MS Neurologist. Mult Scler Relat Disord. 2021 May; 50:102847. PMID: 33618121.
      Citations:    
    18. Cree BAC, Bowen JD, Hartung HP, Vermersch P, Hughes B, Damian D, Hyvert Y, Dangond F, Galazka A, Grosso M, Jones DL, Leist TP. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study. Mult Scler Relat Disord. 2021 Apr; 49:102695. PMID: 33578191.
      Citations:    
    19. Rammohan K, Coyle PK, Sylvester E, Galazka A, Dangond F, Grosso M, Leist TP. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review. Drugs. 2020 Dec; 80(18):1901-1928. PMID: 33247831.
      Citations:    
    20. Leist T, Cook S, Comi G, Montalban X, Giovannoni G, Nolting A, Damian D, Syed S, Galazka A. Long-term safety data from the cladribine tablets clinical development program in multiple sclerosis. Mult Scler Relat Disord. 2020 Nov; 46:102572. PMID: 33296971.
      Citations:    
    21. Giovannoni G, Galazka A, Schick R, Leist T, Comi G, Montalban X, Damian D, Dangond F, Cook S. Pregnancy Outcomes During the Clinical Development Program of Cladribine in Multiple Sclerosis: An Integrated Analysis of Safety. Drug Saf. 2020 Jul; 43(7):635-643. PMID: 32447743.
      Citations:    
    22. Monti DA, Zabrecky G, Leist TP, Wintering N, Bazzan AJ, Zhan T, Newberg AB. N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study. Front Neurol. 2020; 11:88. PMID: 32117038.
      Citations:    
    23. Raphail AA, Vickers KL, Leist TP, Schultheis MT. The Relationship between MS Symptom Severity Measures and Performance on Driving Variability Metrics in a Virtual Reality Simulator. Am J Phys Med Rehabil. 2019 Nov 18. PMID: 31764226.
      Citations:    
    24. Stuve O, Soelberg Soerensen P, Leist T, Giovannoni G, Hyvert Y, Damian D, Dangond F, Boschert U. Effects of cladribine tablets on lymphocyte subsets in patients with multiple sclerosis: an extended analysis of surface markers. Ther Adv Neurol Disord. 2019; 12:1756286419854986. PMID: 31244898.
      Citations:    
    25. Hudgens S, Schüler R, Stokes J, Eremenco S, Hunsche E, Leist TP. Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis. Value Health. 2019 04; 22(4):453-466. PMID: 30975397.
      Citations:    
    26. Cook S, Leist T, Comi G, Montalban X, Giovannoni G, Nolting A, Hicking C, Galazka A, Sylvester E. Safety of cladribine tablets in the treatment of patients with multiple sclerosis: An integrated analysis. Mult Scler Relat Disord. 2019 Apr; 29:157-167. PMID: 30885374.
      Citations:    
    27. Montalban X, Leist TP, Cohen BA, Moses H, Campbell J, Hicking C, Dangond F. Cladribine tablets added to IFN-ß in active relapsing MS: The ONWARD study. Neurol Neuroimmunol Neuroinflamm. 2018 Sep; 5(5):e477. PMID: 30027104.
      Citations:    
    28. Freedman MS, Leist TP, Comi G, Cree BA, Coyle PK, Hartung HP, Vermersch P, Damian D, Dangond F. The efficacy of cladribine tablets in CIS patients retrospectively assigned the diagnosis of MS using modern criteria: Results from the ORACLE-MS study. Mult Scler J Exp Transl Clin. 2017 Oct-Dec; 3(4):2055217317732802. PMID: 29051829.
      Citations:    
    29. Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Hass S, Thangavelu K, Leist TP. Comparing outcomes from clinical studies of oral disease-modifying therapies (dimethyl fumarate, fingolimod, and teriflunomide) in relapsing MS: Assessing absolute differences using a number needed to treat analysis. Mult Scler Relat Disord. 2016 Nov; 10:204-212. PMID: 27919491.
      Citations:    
    30. Comi G, Freedman MS, Kappos L, Olsson TP, Miller AE, Wolinsky JS, O'Connor PW, Benamor M, Dukovic D, Truffinet P, Leist TP. Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions. Mult Scler Relat Disord. 2016 Jan; 5:97-104. PMID: 26856952.
      Citations:    
    31. Rasouli J, Ciric B, Imitola J, Gonnella P, Hwang D, Mahajan K, Mari ER, Safavi F, Leist TP, Zhang GX, Rostami A. Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-ß Therapy. J Immunol. 2015 Jun 1; 194(11):5085-93. PMID: 25917097.
      Citations:    
    32. Freedman MS, Montalban X, Miller AE, Dive-Pouletty C, Leist TP. Assessing the Comparative Outcomes from Teriflunomide and Dimethyl Fumarate Studies in Relapsing Ms: Use of "Number Needed to Treat" Analysis. Value Health. 2014 Nov; 17(7):A392. PMID: 27200909.
      Citations:    
    33. Cohen BA, Coyle PK, Leist T, Oleen-Burkey MA, Schwartz M, Zwibel H. Therapy Optimization in Multiple Sclerosis: a cohort study of therapy adherence and risk of relapse. Mult Scler Relat Disord. 2015 Jan; 4(1):75-82. PMID: 25787057.
      Citations:    
    34. Coyle PK, Cohen BA, Leist T, Markowitz C, Oleen-Burkey M, Schwartz M, Tullman MJ, Zwibel H. Therapy optimization in multiple sclerosis: a prospective observational study of therapy compliance and outcomes. BMC Neurol. 2014; 14(1):49. PMID: 24624979.
      Citations:    
    35. Leist T. Thomas Leist. Lancet Neurol. 2014 Mar; 13(3):244. PMID: 24701631.
      Citations:    
    36. Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014 Mar; 13(3):257-67. PMID: 24502830.
      Citations:    
    37. Leist T, Hunter SF, Kantor D, Markowitz C. Novel therapeutics in multiple sclerosis management: clinical applications. Am J Med. 2014 Jan; 127(1):S2. PMID: 24384114.
      Citations:    
    38. Morse CL, Schultheis MT, McKeever JD, Leist T. Multitasking in multiple sclerosis: can it inform vocational functioning? Arch Phys Med Rehabil. 2013 Dec; 94(12):2509-14. PMID: 23924438.
      Citations:    
    39. Leist TP, Weissert R. Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol. 2011 Jan-Feb; 34(1):28-35. PMID: 21242742.
      Citations:    
    40. Leist TP, Marks S. Magnetic resonance imaging and treatment effects of multiple sclerosis therapeutics. Neurology. 2010 Jan 5; 74 Suppl 1:S54-61. PMID: 20038764.
      Citations:    
    41. Techavipoo U, Okai AF, Lackey J, Shi J, Dresner MA, Leist TP, Lai S. Toward a practical protocol for human optic nerve DTI with EPI geometric distortion correction. J Magn Reson Imaging. 2009 Oct; 30(4):699-707. PMID: 19787713.
      Citations:    
    42. Techavipoo U, Lackey J, Shi J, Leist T, Lai S. Phase labeling using sensitivity encoding (PLUS): data acquisition and image reconstruction for geometric distortion correction in EPI. Magn Reson Med. 2009 Mar; 61(3):650-8. PMID: 19097237.
      Citations:    
    43. Spain RI, Leist TP, De Sousa EA. When metals compete: a case of copper-deficiency myeloneuropathy and anemia. Nat Clin Pract Neurol. 2009 Feb; 5(2):106-11. PMID: 19194390.
      Citations:    
    44. Spain RI, Maltenfort M, Sergott RC, Leist TP. Thickness of retinal nerve fiber layer correlates with disease duration in parallel with corticospinal tract dysfunction in untreated multiple sclerosis. J Rehabil Res Dev. 2009; 46(5):633-42. PMID: 19882496.
      Citations:    
    45. Leist TP, Vermersch P. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. Curr Med Res Opin. 2007 Nov; 23(11):2667-76. PMID: 17880754.
      Citations:    
    46. Butzkueven H, Chapman J, Cristiano E, Grand'Maison F, Hoffmann M, Izquierdo G, Jolley D, Kappos L, Leist T, P?hlau D, Rivera V, Trojano M, Verheul F, Malkowski JP. MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler. 2006 Dec; 12(6):769-74. PMID: 17263005.
      Citations:    
    47. Kasper LH, Everitt D, Leist TP, Ryan KA, Mascelli MA, Johnson K, Raychaudhuri A, Vollmer T. A phase I trial of an interleukin-12/23 monoclonal antibody in relapsing multiple sclerosis. Curr Med Res Opin. 2006 Sep; 22(9):1671-8. PMID: 16968570.
      Citations:    
    48. Okai AF, Muppidi S, Bagla R, Leist TP. Progressive necrotizing myelopathy: part of the spectrum of neuromyelitis optica? Neurol Res. 2006 Apr; 28(3):354-9. PMID: 16687065.
      Citations:    
    49. Oh U, Yamano Y, Mora CA, Ohayon J, Bagnato F, Butman JA, Dambrosia J, Leist TP, McFarland H, Jacobson S. Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol. 2005 Apr; 57(4):526-34. PMID: 15786444.
      Citations:    
    50. Banisor I, Leist TP, Kalman B. Involvement of beta-chemokines in the development of inflammatory demyelination. J Neuroinflammation. 2005 Feb 24; 2(1):7. PMID: 15730561.
      Citations:    
    51. Vyshkina T, Shugart YY, Birnbaum G, Leist TP, Kalman B. Association of haplotypes in the beta-chemokine locus with multiple sclerosis. Eur J Hum Genet. 2005 Feb; 13(2):240-7. PMID: 15494740.
      Citations:    
    52. Vyshkina T, Banisor I, Shugart YY, Leist TP, Kalman B. Genetic variants of Complex I in multiple sclerosis. J Neurol Sci. 2005 Jan 15; 228(1):55-64. PMID: 15607211.
      Citations:    
    53. Zivadinov R, Leist TP. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging. 2005; 15(4 Suppl):10S-21S. PMID: 16385015.
      Citations:    
    54. Vyshkina T, Leist TP, Shugart YY, Kalman B. CD45 (PTPRC) as a candidate gene in multiple sclerosis. Mult Scler. 2004 Dec; 10(6):614-7. PMID: 15584483.
      Citations:    
    55. Kalman B, Leist TP. Familial multiple sclerosis and other inherited disorders of the white matter. Neurologist. 2004 Jul; 10(4):201-15. PMID: 15245586.
      Citations:    
    56. Markovic-Plese S, Bielekova B, Kadom N, Leist TP, Martin R, Frank JA, McFarland HF. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology. 2003 Jun 10; 60(11):1849-51. PMID: 12796549.
      Citations:    
    57. Kalman B, Leist TP. A mitochondrial component of neurodegeneration in multiple sclerosis. Neuromolecular Med. 2003; 3(3):147-58. PMID: 12835510.
      Citations:    
    58. Kalman B, Albert RH, Leist TP. Genetics of multiple sclerosis: determinants of autoimmunity and neurodegeneration. Autoimmunity. 2002 Jul; 35(4):225-34. PMID: 12482189.
      Citations:    
    59. Frank JA, Richert N, Lewis B, Bash C, Howard T, Civil R, Stone R, Eaton J, McFarland H, Leist T. A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients. Mult Scler. 2002 Feb; 8(1):24-9. PMID: 11936485.
      Citations:    
    60. Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowskil H. Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease. Mult Scler. 2001 Oct; 7(5):313-9. PMID: 11724447.
      Citations:    
    61. Richert ND, Ostuni JL, Bash CN, Leist TP, McFarland HF, Frank JA. Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler. 2001 Feb; 7(1):49-58. PMID: 11321194.
      Citations:    
    62. Leist TP, Gobbini MI, Frank JA, McFarland HF. Enhancing magnetic resonance imaging lesions and cerebral atrophy in patients with relapsing multiple sclerosis. Arch Neurol. 2001 Jan; 58(1):57-60. PMID: 11176937.
      Citations:    
    63. Nagai M, Kubota R, Greten TF, Schneck JP, Leist TP, Jacobson S. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis. 2001 Jan 15; 183(2):197-205. PMID: 11120926.
      Citations:    
    64. Muraro PA, Leist T, Bielekova B, McFarland HF. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis. J Neuroimmunol. 2000 Nov 01; 111(1-2):186-94. PMID: 11063837.
      Citations:    
    65. Soldan SS, Leist TP, Juhng KN, McFarland HF, Jacobson S. Increased lymphoproliferative response to human herpesvirus type 6A variant in multiple sclerosis patients. Ann Neurol. 2000 Mar; 47(3):306-13. PMID: 10716249.
      Citations:    
    66. Azimi N, Jacobson S, Leist T, Waldmann TA. Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. J Immunol. 1999 Oct 01; 163(7):4064-72. PMID: 10491011.
      Citations:    
    67. Soldan SS, Graf MD, Waziri A, Flerlage AN, Robinson SM, Kawanishi T, Leist TP, Lehky TJ, Levin MC, Jacobson S. HTLV-I/II seroindeterminate Western blot reactivity in a cohort of patients with neurological disease. J Infect Dis. 1999 Sep; 180(3):685-94. PMID: 10438355.
      Citations:    
    68. Lehky TJ, Levin MC, Kubota R, Bamford RN, Flerlage AN, Soldan SS, Leist TP, Xavier A, White JD, Brown M, Fleisher TA, Top LE, Light S, McFarland HF, Waldmann TA, Jacobson S. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol. 1998 Dec; 44(6):942-7. PMID: 9851439.
      Citations:    
    69. Greten TF, Slansky JE, Kubota R, Soldan SS, Jaffee EM, Leist TP, Pardoll DM, Jacobson S, Schneck JP. Direct visualization of antigen-specific T cells: HTLV-1 Tax11-19- specific CD8(+) T cells are activated in peripheral blood and accumulate in cerebrospinal fluid from HAM/TSP patients. Proc Natl Acad Sci U S A. 1998 Jun 23; 95(13):7568-73. PMID: 9636190.
      Citations:    
    70. Leist TP, Zinkernagel RM. Effects of treatment with IL-2 receptor specific monoclonal antibody in mice. J Immunol. 1990 Apr 01; 144(7):2847. PMID: 2108217.
      Citations:    
    71. Leist TP, Kohler M, Zinkernagel RM. Impaired generation of anti-viral cytotoxicity against lymphocytic choriomeningitis and vaccinia virus in mice treated with CD4-specific monoclonal antibody. Scand J Immunol. 1989 Dec; 30(6):679-86. PMID: 2532394.
      Citations:    
    72. Leist TP, Kohler M, Eppler M, Zinkernagel RM. Effects of treatment with IL-2 receptor specific monoclonal antibody in mice. Inhibition of cytotoxic T cell responses but not of T help. J Immunol. 1989 Jul 15; 143(2):628-32. PMID: 2544648.
      Citations:    
    73. Leist TP, Heuchel R, Zinkernagel RM. Increased bactericidal macrophage activity induced by immunological stimuli is dependent on interferon (IFN)-gamma. Interference of anti-IFN-gamma but not anti-IFN-alpha/beta with modulation of macrophage activity caused by lymphocytic choriomeningitis virus infection or systemic graft-vs.-host reactions. Eur J Immunol. 1988 Aug; 18(8):1295-8. PMID: 3138138.
      Citations:    
    74. Keller R, Keist R, Van der Meide PH, Groscurth P, Aguet M, Leist TP. Induction, maintenance, and reinduction of tumoricidal activity in bone marrow-derived mononuclear phagocytes by Corynebacterium parvum. Evidence for the involvement of a T cell- and interferon-gamma-independent pathway of macrophage activation. J Immunol. 1987 Apr 01; 138(7):2366-71. PMID: 3104463.
      Citations:    
    75. Leist TP, Cobbold SP, Waldmann H, Aguet M, Zinkernagel RM. Functional analysis of T lymphocyte subsets in antiviral host defense. J Immunol. 1987 Apr 01; 138(7):2278-81. PMID: 2435794.
      Citations:    
    Leist's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (243)
    Explore
    _
    Co-Authors (12)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _
    Physical Neighbors
    _